Table 3.
Clinical and CMR characteristics of patients from Montréal
| Normal finding, n = 25 | Amyloidosis, n = 4 | DCM, n = 30 | HCM, n = 17 | HHD, n = 12 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Clinical characteristics | ||||||||||
| Age (years) | 49.7 ± 18.2 | 72.3 ± 17.9 | 57.4 ± 12.3 | 55.4 ± 11.5 | 60.0 ± 13.0 | |||||
| Gender, n (female/male) | 9/16 | 2/2 | 9/21 | 6/11 | 3/9 | |||||
| BMI (kg/m2) | 26.9 ± 5.6* | 23.9 ± 4.0 | 28.3 ± 5.1* | 28.4 ± 4.5* | 29.4 ± 6.3* | |||||
| NT-proBNP (µg/ml) | N/A | 753.0, n = 1 | 321.6 (36–858)*, n = 11 | 198.5 (22–375), n = 2 | 120.0, n = 1 | |||||
| Creatinine (µmol/l) | 76.2 ± 15.13, n = 15 | 109.7 ± 46.3, n = 3 | 92.6 ± 22.4, n = 22 | 82.2 ± 10.6, n = 11 | 88.4 ± 24.1, n = 5 | |||||
| Hypertension, n | 6 | n = 17 | 1 | n = 3 | 9 | n = 25 | 5 | n = 9 | 6 | n = 6 |
| Diabetes mellitus, n | 1 | 1 | 2 | 2 | 2 | |||||
| Hyperlipidaemia, n | 5 | 2 | 4 | 5 | 3 | |||||
| Smoking history, n | 1 | 0 | 7 | 0 | 0 | |||||
| Familiy history of CVD | 4 | 0 | 3 | 3 | 1 | |||||
| CMR characteristics | ||||||||||
| LVEDV (ml/m2) | 69.7 ± 18.0* | 65.2 ± 36.79* | 132.8 ± 39.6* | 64.2 ± 16.4* | 68.0 ± 20.3* | |||||
| LVESV (ml/m2) | 25.1 ± 10.0* | 17.5 ± 17.73 | 92.3 ± 34.6* | 16.7 ± 9.2* | 31.1 ± 17.1 | |||||
| LVEF (%) | 64.5 ± 7.5 | 46.0 ± 14.0* | 31.2 ± 9.4* | 74.5 ± 10.2* | 56.3 ± 13.1 | |||||
| LV mass (g/m2) | 63.1 ± 12.6* | 131.8 ± 32.7* | 103.7 ± 29.8* | 103.1 ± 29.2* | 88.7 ± 35.2* | |||||
| septal thickness (mm) | 8.8 ± 3.1 | 14.7 ± 2.1* | 8.9 ± 2.1 | 13.6 ± 3.3* | 11.2 ± 1.8* | |||||
| Native T1 value at 3T (ms) | 1,241.0 ± 29.7 | 1,439.5 ± 71.1* | 1,306.1 ± 34.4* | 1,292.2 ± 34.5* | 1,300.8 ± 32.7* | |||||
*p < 0.05 when compared to healthy volunteers from Table 1